Latest News and Press Releases

SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...

Excision to give three oral presentations and outline new data in three posters from preclinical programs for herpes keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV) as well as a...

Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101No serious adverse events or dose-limiting toxicities were seen in...

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases,...

Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primatesData are a key component of scientific rationale supporting the ongoing...

EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and...

SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases,...

Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of viral disease, and the Company’s ongoing Phase 1/2 trial evaluating the...

CIRM Grant of $6.85 million supports the first-in-human clinical study evaluating the safety and efficacy of EBT-101 in participants people living with HIVEBT-101 is an in vivo CRISPR-based...